Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus
Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours in pat...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2004-01, Vol.64 (22), p.2577-2595 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2595 |
|---|---|
| container_issue | 22 |
| container_start_page | 2577 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 64 |
| creator | CHAPMAN, Therese M PERRY, Caroline M |
| description | Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours in patients with type 1 or type 2 diabetes mellitus. Insulin detemir has a more predictable, protracted and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycaemic control, compared with NPH insulin or insulin glargine. Insulin detemir, administered once or twice daily, is at least as effective as NPH insulin in maintaining overall glycaemic control, with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia, compared with NPH insulin in patients with type 1 or type 2 diabetes. Insulin detemir also provides the added clinical benefit of no appreciable bodyweight gain in patients with type 1 diabetes and less bodyweight gain than NPH insulin in patients with type 2 diabetes. Insulin detemir is, therefore, a promising new option for basal insulin therapy in patients with type 1 or 2 diabetes. |
| doi_str_mv | 10.2165/00003495-200464220-00008 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67029442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200669281</galeid><sourcerecordid>A200669281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-b78ecbee1bb2c86f6a166ebef4bd7547af2c3ba37e9e6eed361701c94e0f415e3</originalsourceid><addsrcrecordid>eNptkV9rFTEQxYMo9rb6FSQg-rY1_7Px7VK0Fgq-KPgWkuykRnaz101W6bc3671aBJOHkDO_MwxzEMKUXDKq5BvSDhdGdowQoQRjpNuk_hHaUapNR40kj9GOEMo6pZQ-Q-elfNu-Rpqn6IxKSRWVeoe-3OSyjinjASpMaXmL93iBHwl-4jniVAteC-BWr18BTy67O5gg161Y7w-AKXZ5wAwPyfnWoeAJxjHVtTxDT6IbCzw_vRfo8_t3n64-dLcfr2-u9rdd4JLXzuseggeg3rPQq6gcVQo8ROEHLYV2kQXuHddgQAEMXFFNaDACSBRUAr9Ar499D8v8fYVS7ZRKaEO4DPNarNKEGSFYA18ewTs3gk05znVxYYPtvq1RKcN62qjL_1DtDm07Yc4QU9P_MfRHQ1jmUhaI9rCkyS33lhK7hWX_hGX_hvVb6pv1xWn01U8wPBhP6TTg1QlwJbgxLi6HVB44xSnXxPBfHzSaew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67029442</pqid></control><display><type>article</type><title>Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>CHAPMAN, Therese M ; PERRY, Caroline M</creator><creatorcontrib>CHAPMAN, Therese M ; PERRY, Caroline M</creatorcontrib><description>Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours in patients with type 1 or type 2 diabetes mellitus. Insulin detemir has a more predictable, protracted and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycaemic control, compared with NPH insulin or insulin glargine. Insulin detemir, administered once or twice daily, is at least as effective as NPH insulin in maintaining overall glycaemic control, with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia, compared with NPH insulin in patients with type 1 or type 2 diabetes. Insulin detemir also provides the added clinical benefit of no appreciable bodyweight gain in patients with type 1 diabetes and less bodyweight gain than NPH insulin in patients with type 2 diabetes. Insulin detemir is, therefore, a promising new option for basal insulin therapy in patients with type 1 or 2 diabetes.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.2165/00003495-200464220-00008</identifier><identifier>PMID: 15516157</identifier><identifier>CODEN: DRUGAY</identifier><language>eng</language><publisher>Auckland: Adis International</publisher><subject>Biological and medical sciences ; Clinical Trials as Topic ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 2 - drug therapy ; General and cellular metabolism. Vitamins ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - pharmacokinetics ; Hypoglycemic Agents - therapeutic use ; Insulin - administration & dosage ; Insulin - analogs & derivatives ; Insulin - pharmacokinetics ; Insulin - therapeutic use ; Insulin Detemir ; Insulin, Long-Acting ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Drugs (New York, N.Y.), 2004-01, Vol.64 (22), p.2577-2595</ispartof><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2004 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c353t-b78ecbee1bb2c86f6a166ebef4bd7547af2c3ba37e9e6eed361701c94e0f415e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16313709$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15516157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHAPMAN, Therese M</creatorcontrib><creatorcontrib>PERRY, Caroline M</creatorcontrib><title>Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><description>Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours in patients with type 1 or type 2 diabetes mellitus. Insulin detemir has a more predictable, protracted and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycaemic control, compared with NPH insulin or insulin glargine. Insulin detemir, administered once or twice daily, is at least as effective as NPH insulin in maintaining overall glycaemic control, with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia, compared with NPH insulin in patients with type 1 or type 2 diabetes. Insulin detemir also provides the added clinical benefit of no appreciable bodyweight gain in patients with type 1 diabetes and less bodyweight gain than NPH insulin in patients with type 2 diabetes. Insulin detemir is, therefore, a promising new option for basal insulin therapy in patients with type 1 or 2 diabetes.</description><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - analogs & derivatives</subject><subject>Insulin - pharmacokinetics</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Detemir</subject><subject>Insulin, Long-Acting</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkV9rFTEQxYMo9rb6FSQg-rY1_7Px7VK0Fgq-KPgWkuykRnaz101W6bc3671aBJOHkDO_MwxzEMKUXDKq5BvSDhdGdowQoQRjpNuk_hHaUapNR40kj9GOEMo6pZQ-Q-elfNu-Rpqn6IxKSRWVeoe-3OSyjinjASpMaXmL93iBHwl-4jniVAteC-BWr18BTy67O5gg161Y7w-AKXZ5wAwPyfnWoeAJxjHVtTxDT6IbCzw_vRfo8_t3n64-dLcfr2-u9rdd4JLXzuseggeg3rPQq6gcVQo8ROEHLYV2kQXuHddgQAEMXFFNaDACSBRUAr9Ar499D8v8fYVS7ZRKaEO4DPNarNKEGSFYA18ewTs3gk05znVxYYPtvq1RKcN62qjL_1DtDm07Yc4QU9P_MfRHQ1jmUhaI9rCkyS33lhK7hWX_hGX_hvVb6pv1xWn01U8wPBhP6TTg1QlwJbgxLi6HVB44xSnXxPBfHzSaew</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>CHAPMAN, Therese M</creator><creator>PERRY, Caroline M</creator><general>Adis International</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040101</creationdate><title>Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus</title><author>CHAPMAN, Therese M ; PERRY, Caroline M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-b78ecbee1bb2c86f6a166ebef4bd7547af2c3ba37e9e6eed361701c94e0f415e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - analogs & derivatives</topic><topic>Insulin - pharmacokinetics</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Detemir</topic><topic>Insulin, Long-Acting</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHAPMAN, Therese M</creatorcontrib><creatorcontrib>PERRY, Caroline M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHAPMAN, Therese M</au><au>PERRY, Caroline M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><addtitle>Drugs</addtitle><date>2004-01-01</date><risdate>2004</risdate><volume>64</volume><issue>22</issue><spage>2577</spage><epage>2595</epage><pages>2577-2595</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><coden>DRUGAY</coden><abstract>Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin, thereby providing slow absorption and a prolonged and consistent metabolic effect of up to 24 hours in patients with type 1 or type 2 diabetes mellitus. Insulin detemir has a more predictable, protracted and consistent effect on blood glucose than neutral protamine Hagedorn (NPH) insulin, with less intrapatient variability in glycaemic control, compared with NPH insulin or insulin glargine. Insulin detemir, administered once or twice daily, is at least as effective as NPH insulin in maintaining overall glycaemic control, with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia, compared with NPH insulin in patients with type 1 or type 2 diabetes. Insulin detemir also provides the added clinical benefit of no appreciable bodyweight gain in patients with type 1 diabetes and less bodyweight gain than NPH insulin in patients with type 2 diabetes. Insulin detemir is, therefore, a promising new option for basal insulin therapy in patients with type 1 or 2 diabetes.</abstract><cop>Auckland</cop><pub>Adis International</pub><pmid>15516157</pmid><doi>10.2165/00003495-200464220-00008</doi><tpages>19</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2004-01, Vol.64 (22), p.2577-2595 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67029442 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Biological and medical sciences Clinical Trials as Topic Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - drug therapy General and cellular metabolism. Vitamins Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacokinetics Hypoglycemic Agents - therapeutic use Insulin - administration & dosage Insulin - analogs & derivatives Insulin - pharmacokinetics Insulin - therapeutic use Insulin Detemir Insulin, Long-Acting Medical sciences Pharmacology. Drug treatments |
| title | Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T09%3A58%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin%20detemir:%20A%20review%20of%20its%20use%20in%20the%20management%20of%20type%201%20and%202%20diabetes%20mellitus&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=CHAPMAN,%20Therese%20M&rft.date=2004-01-01&rft.volume=64&rft.issue=22&rft.spage=2577&rft.epage=2595&rft.pages=2577-2595&rft.issn=0012-6667&rft.eissn=1179-1950&rft.coden=DRUGAY&rft_id=info:doi/10.2165/00003495-200464220-00008&rft_dat=%3Cgale_proqu%3EA200669281%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67029442&rft_id=info:pmid/15516157&rft_galeid=A200669281&rfr_iscdi=true |